/PRNewswire/ The "Allogeneic Cell Therapy: Global Market Report 2023-2035" report has been added to ResearchAndMarkets.com s offering. The global allogeneic.
/PRNewswire/ Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in.